MindMed Says it is Fully Funded Through 2025

The company has high expectations for its MM-120 LSD drug.

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (NEO: MMED) reported its financial results for the second quarter ending on June 30. The company has no revenue to report at this time, but the net loss for the quarter increased to $29.1 million versus last year’s net loss of  $17 million for the same period in 2022.

It did note that it had cash and cash equivalents totaling $116.9 million versus $142.1 million as of Dec. 31, 2022. MindMed said it believes it has enough money to fund its operations into the first half of 2025.

“We’re coming up on a critical period for MindMed as we are close to wrapping up enrollment in our Phase 2b study of MM-120 for the treatment of generalized anxiety disorder (GAD),” said Robert Barrow, chief executive officer and director. “Our ability to enroll a study of this size in such an efficient manner stands out in the field and speaks to the remarkable quality of our R&D team. We are also excited to have licensed Catalent’s Zydis ODT technology for use with MM-120 which we believe significantly bolsters the differentiation and protectability of our MM-120 product candidate while potentially offering enhanced bioavailability and more rapid absorption, which may lead to a shorter treatment session.”


MindMed reported that the operating expenses were $29 million in the second quarter versus $16 million for the same time period in 2022.

Research and development expenses were $14.8 million for the quarter versus $9.3 million for the quarter in 2022, an increase of $5.5 million. The company said the increase was primarily due to increases of:

  • $4.4 million in expenses related to clinical research for the MM-120, MindMed’s LSD drug, GAD study.
  • $800,000 in preclinical activities
  • $600,000 in internal personnel costs as a result of increasing R&D capacity
  • $200,000 in connection with various external R&D collaborations

Those increases were partially offset by a decrease of $500,000 in expenses related to the MM-110 program and a decrease of $100,000 related to the MM-402 program.

Post Board Battle

MindMed is coming off a bruising battle for control of the company. Last month, shareholders voted for the board members who wanted to pursue more research at the Phase II level for MM-120, while a group called FCM MM Holdings fought for a faster track to a Phase III study.

The company said that a topline readout of MM-120 in GAD (Phase 2b) is expected in the fourth quarter of 2023 with enrollment to be concluded in the third quarter of 2023.

“It is our aim that with compelling clinical data from our Phase IIb study, our proprietary form of LSD MM-12 will become one of the leading candidates, if not the leading candidate, in the psychedelic drug class,” Barrow said on the company’s latest earnings call.

He went on to say that the Phase 2b study of MM-120 and GAD is the largest controlled study of LSD ever conducted and will guide the dose selection and development strategy for MM-120. However, he also noted that the patient population size was reduced from 200 to 180.

“We are also encouraged by the recent growth and uptake of Janssen’s Spravato nasal spray, which similarly utilizes a session-based delivery paradigm to the lack of a durable treatment response for Spravato requires patients to spend over 12 hours in the clinical study across six or more visits in the first month of treatment alone,” Barrow added.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.